Summary

This article reports the results of the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation—TIMI 48 trial [ENGAGE AF-TIMI 48]. This randomized, double-blind, double-dummy trial of 21,105 patients demonstrated the efficacy and safety of a once-daily regimen of the oral anticoagulant edoxaban in treatment of atrial fibrillation (AF). The primary trial results have been published [Giugliano RP et al. N Engl J Med 2013].